This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
McKesson (MCK) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Top-line growth and better-than-expected segmental performance are likely to aid McKesson (MCK) in Q1. However, rise in adjusted operating expenses is likely to be a dampener.
Can Instruments Drive Intuitive Surgical (ISRG) Q2 Earnings?
by Zacks Equity Research
Intuitive Surgical (ISRG) expects its core Instruments and Accessories unit to boost second-quarter 2019 results.
AngioDynamics (ANGO) Q4 Earnings Miss, Revenues Top Estimates
by Zacks Equity Research
AngioDyamics (ANGO) gains from solid segmental contributions in fourth-quarter fiscal 2019.
Smith & Nephew Acquires Atracsys, Expands Robotic Portfolio
by Zacks Equity Research
With Smith & Nephew's (SNN) buyout of Atracsys, the latter's fusionTrack 500 optical tracking camera will be a core enabling technology for the company's next-generation robotics platform.
Varian to Acquire Boston Scientific's Embolic Bead Products
by Zacks Equity Research
Varian (VAR) expects the buyout to prove accretive to its fiscal 2020 reported and adjusted earnings per share.
Myriad Genetics' Elevate 2020 Plan Holds Promise Amid Issues
by Zacks Equity Research
Myriad Genetics (MYGN) unveils an 'Elevate 2020' program that aims to generate $50 million in incremental operating income by fiscal 2020.
Medtronic's Titan Spine Buyout to Boost Spine Surgery Range
by Zacks Equity Research
Medtronic's (MDT) comprehensive biologics portfolio clubbed with Titan Spine's surface-enhanced titanium implants can enhance patient outcomes in spinal procedures.
Walgreens Gains on Strategic Deals, Margin Pressure Remains
by Zacks Equity Research
Walgreens Boots' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also benefiting from a strong retail prescription market.
Thermo Fisher's Unit Sale May Not Ail Specialty Diagnostics
by Zacks Equity Research
The Anatomical Pathology business of Thermo Fisher (TMO) belongs to its Specialty Diagnostics segment that serves customers across healthcare and clinical laboratories.
Here's Why You Should Hold Varian Medical (VAR) Stock Now
by Zacks Equity Research
Varian (VAR) expects the Cancer Treatment Services International buyout to prove accretive to earnings per share during fiscal 2021.
Amedisys Rides on New Buyouts, Strength in Personal Care Arm
by Zacks Equity Research
Amedisys' (AMED) recently-integrated Personal Care segment is attaining stability and living up to expectation.
Veeva's Vault eTMF Implemented by South Korea's Celltrion
by Zacks Equity Research
Management at Veeva (VEEV) expects Vault subscription revenues to grow a significant 40% in fiscal 2020.
Patterson Companies' (PDCO) Earnings Miss Estimates in Q4
by Zacks Equity Research
Patterson Companies' (PDCO) Q4 results benefit from higher revenues, gross margin expansion and solid show by Animal Health segment.
Varian (VAR) & Tennessee Oncology to Implement Use of Noona
by Zacks Equity Research
Varian's (VAR) core Oncology unit gets a boost from the latest collaboration with Tennessee Oncology.
Here's Why You Should Invest in DENTSPLY SIRONA (XRAY) Now
by Zacks Equity Research
DENTSPLY (XRAY) focuses on innovation through active R&D.
Veeva's Submissions & RIM Implemented by Sumitomo Dainippon
by Zacks Equity Research
Veeva's (VEEV) flagship Vault platform witnesses robust demand.
Here's Why You Should Buy Masimo (MASI) Stock Right Now
by Zacks Equity Research
Masimo (MASI) receives FDA clearance for its O3 Regional Oximetry for utilization on neonatal and infant patients.
What's in Store for Patterson Companies (PDCO) in Q4 Earnings?
by Zacks Equity Research
Patterson Companies (PDCO) expects to gain from the Animal Health unit in fourth-quarter fiscal 2019.
DaVita Divests DMG to Optum, Boosts Kidney Care Services
by Zacks Equity Research
The divestment of DMG boosts DaVita's (DVA) core Kidney Care business.
Here's Why You Should Hold PerkinElmer (PKI) Stock for Now
by Zacks Equity Research
PerkinElmer (PKI) raises earnings per share guidance for 2019.
What Makes Dentsply International (XRAY) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Dentsply International (XRAY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Merit Medical Acquires Brightwater Medical for $35 Million
by Zacks Equity Research
The Brightwater Medical-acquisition broadens Merit Medical's (MMSI) product offerings.
Here's Why You Should Hold Baxter International (BAX) for Now
by Zacks Equity Research
Baxter (BAX) expects its bottom line to rise in the second quarter of 2019, courtesy to Renal Care and Clinical Nutrition businesses.
Medidata (MDSO) to be Acquired by Dassault for $5.8 Billion
by Zacks Equity Research
Dassault's acquisition of Medidata (MDSO) to close by 2019-end.
Ecolab's (ECL) New Digital Dashboards to Improve Healthcare
by Zacks Equity Research
Ecolab's (ECL) Hand Hygiene Compliance Monitoring System connects with digital dashboards.